24/01/2026
الحمد لله مقاله تحقیقی ما تحت عنوان «Potent P2Y12 Inhibitor Monotherapy versus Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Systematic Review and Meta-Analysis» در یکی از ژورنال های معتبر Sage قبول گردیده تا نشر شود که خلاصه آن قرار ذیل می باشد:
🔍 Key findings from 10 RCTs (35,277 patients):
* Early aspirin discontinuation with P2Y12 inhibitor monotherapy after 1–3 months of DAPT
* Significant reduction in bleeding (BARC 3 or 5)
* Lower net adverse clinical events (NACE)
* No increase in ischemic risk (MACE, MI, stroke, stent thrombosis, or mortality)
📌 Conclusion:
P2Y12 inhibitor monotherapy (ticagrelor or prasugrel-based) after short-term DAPT is a safe, effective, and bleeding-sparing alternative to conventional 12-month DAPT in ACS patients post-PCI.
